 |
|
|
|
|
|
|
|
|
We welcome your feedback, comments and suggestions. Please feel free to contact
us if you have a question or to send us your ideas for improving this site.
|
|
| |
|
Vice President of Healthcare Risk Services
Tom Snyder x5852
Manager, Healthcare Risk Services
Phyllis DeCola x5897
|
|
|
|
|
|
|
 |
|
Ask the Expert: Risk Management Considerations
General risk management considerations
-
Until such time as a protocol is agreed upon by the medical/dental community, use conservative approaches that best reflect current literature
-
Networking with medical colleagues and your specialty professional organizations to establish a pre-therapeutic regimen for patients requiring bisphosphonates
-
Initiation of bisphosphonate therapy should be pre-empted by a dental/maxillofacial assessment, whenever possible
-
Treatment of all invasive or potentially problematic dental conditions should be completed prior to aggressive bisphosphonate therapy
-
Conducting a thorough medical history, including a review of current and previous medical conditions as well as medications
-
Proceeding very cautiously with all surgically invasive procedures on patients who have received intravenous infusion of high doses of bisphosphonates over a prolonged period of time
-
Consulting with medical colleagues to obtain total dosage history and discuss potential patient risks
-
Carefully executing your informed consent discussion and documentation of all material risks, benefits and alternatives to treatment
-
Thoroughly document all findings, diagnoses, consultations, plans, treatment and rationale, as well as, post-operative instructions and follow-up
|
|
|
|
|
|